Shots:

• Genesis to receive a total deal value of ~$670M including $20M up front, target nomination, preclinical, development, regulatory & sales milestones along with royalties. The companies collaborated on three initial targets across therapeutic areas
• Lilly to get an option to nominate targets for additional nomination payments/target. Additionally, Genesis and Lilly’s engineers and scientists will use the Genesis’ field-leading machine learning models
• The collaboration will utilize Genesis’ AI drug discovery platform which combines 3D structure-aware deep neural networks & cutting-edge molecular simulation to discover novel therapies for patients suffering from severe diseases

Ref: Businesswire | Image: Businesswire